13. Retirement benefit obligations GROUP The majority of the employees of the Group are covered by retirement benefit plans paid for by the companies of the Group. The types of plan vary according to regulatory requirements, tax rules and economic conditions in the countries in which the employees are employed. A summary of the most important plans is given below. Defined contribution plans For the defined contribution plans, the employer undertakes to pay a defined contribution (e.g. a fixed amount or a fixed percentage of the pay). Under a defined contribution plan, the employees will usually bear the risk related to future developments in interest and inflation rates etc. The major defined contribution plans cover employees in Finland, Sweden, Switzerland and the UK and also salaried staff and hourly paid workers in Denmark. The cost of defined contribution plans, representing contributions to the plans, totalled DKK 62.1 million in 2000 (DKK 49.5 million in 1999). Defined benefit plans For the defined benefit plans, the employer undertakes to pay a defined benefit (e.g. a retirement pension at a fixed amount or a fixed percentage of the employees final salary). Under the defined benefit plan, the company usually bears the risk relating to future developments in interest and inflation rates etc. For defined benefit plans, the present value of future benefits, which the company is liable to pay under the plan, is computed using actuarial principles. The computation of present value is based on assumptions about basic interest rates, increases in pay rates and pensions, investment yield, staff resignation rates, mortality and disability. Present value is computed exclusively for the benefits to which the employees have earned entitlement through their employment with the company. The Groups most important defined benefit plans cover employees in the UK and Germany. The UK defined benefit plan is funded by means of an independent pension fund. The liability under the plan calculated on an actuarial basis is recorded in the consolidated balance sheet at 31 December 2000 at an amount of DKK 13.3 million. The liability is calculated as the present value of the future payments of DKK 128.5 million less the marke value of the pension funds assets of DKK 115.2 million. The actuarial calculation is based on a discount rate of 5% p.a., a pay rate increase of 4.0% p.a. and a pension increase of 2.5% p.a. The calculation does not include an ageweighted staff resignation rate. The consolidated income statement for 2000 includes an expense of DKK 13.6 million (DKK 0 million in 1999). Actuarial losses on the plan are recognised as an expense in the income statement. The German defined benefit plan is not funded. The liability under the plan calculated on an actuarial basis is stated in the consolidated balance sheet at 31 December 2000 at an amount of DKK 59.3 million (DKK 47.6 million in 1999). The actuarial calculation is based on a discount rate of 6.5% p.a., a pay rate increase of 3.5% p.a., a pension increase of 6.2% every third year and an age-weighted staff resignation rate of 0-5% p.a. The consolidated income statement for 2000 includes an expense of DKK 19.7 million for the plan (DKK 11.6 million in 1999). Actuarial losses on the plan are recognised as an expense in the income statement. In addition, the Group has defined benefit plans in Belgium and Norway, which are also unfunded. The liability under these plans is recorded in the consolidated balance sheet at 31 December 2000 at an amount of DKK 0.2 million (DKK 6.6 million in 1999). The consolidated income statement for 2000 includes an expense on the plans of DKK 0.9 million (DKK 2.8 million in 1999). Termination benefit schemes In 2000, the Group made a provision of DKK 13.2 million (DKK 8.2 million in 1999) to cover termination benefits in Germany, Austria, Italy and Greece. The termination benefit payments are conditional upon specified requirements being met. The total cost of the schemes was DKK 5.6 million in 2000 (DKK 2.1 million in 1999). Other payments In addition to the above plans, the companies of the Group make payments to certain statutory or contract-based benefit schemes for employees of a nature similar to social, retirement benefit or insurance plans. The annual contributions to these plans are recognised as part of the Groups overall staff costs. The costs paid in 2000 totalled DKK 114.3 million (DKK 91.9 million in 1999). H. LUNDBECK A/S 85 ACCOUNTS
Årsberetning 1999 Annual Report 2000
2000 was a very satisfactory year for H. Lundbeck A/S. In the year 2000 the company achieved its bes
Supervisory Board 1 2 3 4 5 6 7 8 9 1 ARNE V. JENSEN (Chairman) Directorships Lundbeckfonden
Corporate Management Group 1 3 4 5 2 6 7 8 Board of Management 1 Senior Vice Presidents 3 ER
Contents CHANGE REPORT GROUP FINANCIAL 5 6 7 2000 HIGHLIGHTS 1996-2000 MEMORIES OF A PSYCHOPHARMA
In Northern Italy, on the boundary between Liguria and Toscana, lies the port of Carrara, neighbour
Change To have high goals and establish a creative forum. To combine experience and vision. To coup
Report 2000 Changes in accounting policies The years important events In February, Lundbecks UK sub
Net profit for the year (DKKm) 1.000 900 800 700 600 500 400 300 200 100 0 1996 Net profit ratio Net
Revenue worldwide 11% Revenue by product 18% 21% 20% 62% 68% Europe USA Rest of world Cipramil®
Income from Celexa® (DKKm) 1.400 1.200 20% 1.000 800 600 400 5% 200 0 1996 1997 1998 1999 2000 0 15%
Number of employees at year-end 3.500 3.000 2.500 2.000 1.500 1.000 500 0 1996 1997 1998 1999 2000 2
Research and development costs (DKKm) 1.600 1.400 1.200 1.000 800 600 400 200 0 1996 1997 1998 1999
Generic competition The production of citalopram is protected by a large number of strong process pa
Expectations for 2001 Lundbeck expects sales of citalopram to continue rising in 2001, mainly in the
Memories of a Pscyhopharmacologist Changing Minds, Changing Lives By Arvid Carlsson Winning the Nob
Carrara is not just marble. Other reasons why thousands of sculptors go to the region is that it imp
Changing the World From Sweden So, I struck out on my own and went back to Lund to work with Hillarp
It takes knowledge and experience to read the stones reactions when the rough cutting is done with d
mine, the other root molecule identified by us in the early series of amine uptake inhibiting agents
I am afraid that the very nature of depression will limit the possibility of success in these areas.
Look at the long term effects of blocking receptors with neuroleptics. The brain doesnt like it at a
The rough shaping is done by removing large and small chunks with modern, special tools. 21
Conjuring the precise, planned shape out of the recalcitrant block of granite is physically hard wor
Lundbeck has 735 employees in Research and Development, including about 250 in Drug Discovery. Drug
In the summer of 2000, the sequence of the human genome was published. This opened the way for findi
A research process Target identification & validation Disease unmet need Assay development H
Development Lundbeck aims to be a world leader within the development of pharmaceuticals for the tr
Here, the bottom face is adjusted. This is the base from which the sculptor calculates the precise m
Lundbeck has also entered into a research and development agreement with the Danish biotechnology co
Development pipeline per 31.12.2000 Compound Almotriptan Escitalopram Memantine Etilevodopa Rasagili
Escitalopram is the first of the new SSRI* generation Lundbecks new antidepressant, escitalopram, i
Escitalopram developed in a short space of time In the summer of 1997, H. Lundbeck A/S and Forest La
The clinical development programme The clinical effect of escitalopram has been documented in a numb
Here, the block of granite is seen lying down, with the base of the sculpture on the left. Red lines
Lundbecks products Antidepressants Cipramil®/Seropram®/Cipram®/Celexa® (citalopram) Indication: dep
On the face of it, the preliminary phases of the sculptors work may look rather random, but everythi
The modern sculptor naturally makes use of cranes, technical aids and modern tools, but it is still
Growth in a good environment It is Lundbecks mission to improve the quality of life of those suffer
Raw materials consumption (tonnes) 10,000 Environmental performance Lundbecks environmental initiat
Water consumption ( 1,000 m3) 250 Wastewater (1,000 m3) 250 200 200 150 150 100 100 50 50
Energy consumption (MWh) 100,000 Waste (tonnes) 16,000 14,000 80,000 12,000 10,000 8,000 60,000
Statement from Deloitte & Touche We agreed with the Companys management to perform a review of
Shareholder information H. Lundbeck A/Ss shares are listed on the Copenhagen Stock Exchange and wer
Shares traded and stock performance, 2000 700,000 800 600,000 700 500,000 600 400,000 500 300
Share ratios Ratios per share, DKK Earnings (EPS) Cash flow Net asset value Dividend Dividend as a p
Change takes shape 45
Composition of the shareholder group 6% 7% Composition of the shareholder group (excl. LFI A/S) 4%
Announcements to the Copenhagen Stock Exchange from H. Lundbeck A/S in 2000 No. 37 36 35 34 33 32 31
The 5-tonne block of granite has been transformed into an exciting sculpture. Its weight is now down
Financial calendar 2001 Tentative dates 6 27 15 14 6 March 2001 March 2001 May 2001 August 2001 Nove
It is not without reason that artists seek inspiration in the Tuscan landscape around Carrara. In th
Summary for the Group 1993-2000 The comparative figures have been adjusted for changes in accounting
Ratios Net profit ratio (%) Return on assets (%) Return on equity (%) R&D costs as a percentage
Financial review Changes in accounting policies Comparative figures and financial highlights and r
Tax on the policy changes increases net profit for the year by DKK 167 million and reduces deferred
Lundbecks sales of other antidepressants and antipsychotics were DKK 798 million in 2000, a decline
Net exchange gain relating to finance income was DKK 39 million in 2000 compared to DKK 41 million i
In 2000, Lundbecks interest-bearing net cash (the companys holding of cash and cash equivalents less
million. Capital and reserves exclusive of the proposed dividend will amount to DKK 3,560 million af
The options are earned by one-third a year over a three-year period. The first portion could be exer
Effect of incentive plans Treasury shares/current assets DKKm Obligation/ provisions DKKm Staff cost
Employees In 2000, the average number of full-time employees totalled 3,002, an increase of 349 comp
1999 Currencies of the cash inflows of H. Lundbeck A/S and its Danish subsidiaries in 1999 og 2000
Accounting Policies General The parent financial statements and the consolidated financial statemen
Forward contracts and other derivative financial instruments are stated at market value. Both realis
Other operating income and expenses Other operating income and expenses comprise, among other things
Gains and losses are included in the income statement under the same items as the associated depreci
Obligations relating to employees of foreign companies under the share price based plan are included
Income statement for the year ended 31 December 2000 PARENT 1999 DKKm 2,712.7 759.4 420.5 328.9 1,20
Balance sheet at 31 December 2000 Assets PARENT 1999 DKKm 8.2 55.0 63.2 644.7 228.8 144.4 133.5 1,15
Balance sheet at 31 December 2000 Liabilities PARENT 1999 DKKm 1,165.5 448.2 269.9 202.8 695.2 129.6
Cash flow statement for the year ended at 31 December 2000 KONCERN 2000 DKKm 1,004.0 189.7 455.4 1,6
Signatures Copenhagen, 6 March 2001 The Supervisory Board and the Board of Management have today co
Notes 1. Revenue PARENT 1999 DKKm 308.8 1,750.1 533.7 120.1 2,712.7 23.0 141.5 2000 DKKm 295.6 2,30
2. Staff costs continued Incentive plans: In 1999, the company introduced a share option plan for
Notes 3. Depreciation and amortisation PARENT 1999 DKKm 2000 DKKm Depreciation and amortisation in
6. Income tax expense PARENT 1999 DKKm 154.0 1.4 2000 DKKm 498.7 (0.5) Current tax Prior year adjust
Notes 7. Intangible and tangible assets GROUP Goodwill Product rights DKKm 40.1 18.4 58.5 31.9 7.2
GROUP Land and buildings DKKm 878.2 22.2 261.8 30.5 4.7 1,188.0 211.5 9.8 10.4 46.1 2.0 275.8 912.2
Notes 8. Investments in subsidiaries Total DKKm Carrying amount at 1.1.2000 Capital contribution Di
8. Investments in subsidiaries continued Currency Nominel capital `000 200 1,000 200 400 5 60 500
Notes 9. Other investments and other receivables PARENT Other investments DKKm 103.2 Receivables fr
12. Capital and reserves GROUP Share capital DKKm 1999 Capital and reserves at 1.1.1999 Adjustment d
Notes 12. Capital and reserves continued PARENT Share capital Share premium Reserve for net reval
13. Retirement benefit obligations GROUP The majority of the employees of the Group are covered by r
Notes 14. Deferred tax liabilities GROUP Temporary differences between assets and liabilities as st
14. Deferred tax liabilities continued PARENT Temporary differences between assets and liabilities
Notes 15. Other provisions GROUP Share options for Group management and key employees DKKm Provisio
16. Non-current liabilities PARENT 1999 DKKm 15.9 2000 DKKm 14.2 Mortgage debt due after 5 years 200
Notes 17. Contractural obligations Rental and leasing obligations Lundbeck has obligations amountin
18. Contingent liabilities Letters of intent The parent has issued letters of intent to subsidiaries
Notes 19. Financial instruments continued Credit risks The primary financial instruments shown in
20. Related parties Lundbeck defines related parties as: the companys principal shareholder, LFI A
Notes 22. Earnings per share (EPS) Earnings per share (EPS) are calculated as: (profit after tax an
25. Acquisition of companies In 2000, Lundbeck acquired 78.29% of the share capital of VIS Farmaceut
Summary for 1999-2000 by quarter The tables show financial highlights by quarter according to the ne
New accounting policies (DKKm) Financial highlights by quarter: Q1 - 1999 Revenue Profit from operat
Lundbeck Worldwide For further information please see our homepage: www.lundbeck.com Parent Company
On its way to its final position between Lundbecks coming canteen and the new head office, which are
Photos Thomas Grøndahl, Steen Vedel Design og production Creavision A/S Reproduction Highlight Grafi
Annual Report 2000 H. Lundbeck A/S 9 Ottiliavej DK-2500 Copenhagen Valby Denmark Tel.: +45 3630